The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Jinhe Biotechnology CO., Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.40% CNY4.34
America/New_York / 6 mai 2024 @ 02:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 387.03 mill |
| EPS: | 0.120 |
| P/E: | 36.17 |
| Earnings Date: | Apr 28, 2024 |
| SharesOutstanding: | 780.42 mill |
| Avg Daily Volume: | 14.95 mill |
| RATING 2024-05-06 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.01x |
| Company: PE 36.17 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.79x |
| Company: PE 36.17 | industry: PE 45.57 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
CNY 4.06 - 4.44 ( +/- 4.40%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY4.34 (1.40% ) |
| Volume | 19.81 mill |
| Avg. Vol. | 14.95 mill |
| % of Avg. Vol | 132.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 002688.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
002688.SZ
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera. It also exports its products to the United States, South-east Asia, Latin America, Europe, etc. The company was founded in 1990 and is based in Dalian, China.